SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
The factor that changes everything. A critical break. A sudden change in plans. A threat and a danger. Recover from the blow and get back on course. Severe stress. Withstand the blow.
Immunology and inflammation
Aldeyra Cans RASP Asset, Brings Forward Two Others in Pipeline Shakeup
The reprioritization initiative extends Aldeyra’s cash runway into the second half of 2027.
October 29, 2025
 · 
2 min read
 · 
Tristan Manalac
People And Robots Handshake Modern Human And Artificial Intelligence Futuristic Mechanism Technology Vector Illustration
Artificial intelligence
J&J, Lilly Crest AI Wave With Nvidia Partnerships
Eli Lilly and Johnson & Johnson are joining fellow Big Pharma peers in upping their investment in AI, with Lilly looking to create the industry’s ‘most powerful supercomputer’ and J&J building a virtual operating room.
October 29, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
Novartis’ Big Buy, Q3 Earnings, Regeneron’s Dropped Cell Therapy, More
As third-quarter earnings continue to roll out, Novartis makes headlines with the second biggest acquisition of the year; Novartis’ CEO also downplayed the impact of Big Pharma pricing deals with the Trump administration; Regeneron continued the trend of dropping cell therapy assets; BioSpace takes a look at how the FDA is functioning mid-shutdown.
October 29, 2025
 · 
1 min read
 · 
Heather McKenzie
USA shutdown and United States government closed and american federal shut down due to spending bill disagreement between the left and the right pas a national finance symbol with yellow hazard tape in a 3D illustration style.
Government
FDA Struggles To Keep Lights On Amid Shutdown as Biopharmas Begin To See Delays
While the FDA continues to put out guidance documents and approve drugs, some companies are already reporting delays in dealings with the agency, while insiders warn of falling morale and a negative perception from the rest of the biopharma world.
October 29, 2025
 · 
4 min read
 · 
Dan Samorodnitsky
Big fish eat small fish, in a competitive business market who has more resources or having more bargaining power is a win. But we can overcome them by being different.
Mergers & acquisitions
5 SMID-Cap Pharmas Poised for M&A Action
Mergers and acquisitions are not just for Big Pharma. A new report from Leerink Partners takes a stab at identifying the small- to mid-cap pharmas best prepared to bolster their pipelines with a buyout.
October 29, 2025
 · 
7 min read
 · 
Annalee Armstrong
A hand in a medical or laboratory glove holds a laboratory flask with coins with dollar sign. Investments in laboratory research and science. Concept of profit, making money, business. Modern design. Copy space.
Earnings
Novartis CEO Says Trump’s Drug Pricing Deals Don’t Address Root Problem
Vas Narasimhan confirmed that Novartis is having weekly discussions with the Trump administration on drug pricing, but a deal has not yet been reached.
October 28, 2025
 · 
3 min read
 · 
Annalee Armstrong
Blue human kidneys with a red surface. Kidney disease, medical diagnosis, technology, artificial intelligence, treatment concept. Low-poly futuristic digital style. Wireframe structure. Vector.
Autoimmune disease
Cabaletta’s CAR T Therapy Spurs Remissions in Small Lupus Trial
Phase I/II data for rese-cel point to its therapeutic potential in systemic lupus erythematosus and lupus nephritis, as well as other autoimmune conditions.
October 28, 2025
 · 
2 min read
 · 
Tristan Manalac
Sep 21, 2020 Brisbane / CA / USA - BioMarin headquarters in Silicon Valley; BioMarin Pharmaceutical Inc. is an American biotechnology company
Earnings
BioMarin Abandons Gene Therapy Roctavian, Cuts Revenue Guidance as Voxzogo Faces Competitors
BioMarin no longer expects to hit its $4 billion revenue target by 2027, citing various market factors such as impending competition for achondroplasia therapy Voxzogo and the divestment of the gene therapy Roctavian.
October 28, 2025
 · 
4 min read
 · 
Tristan Manalac
Cambridge, USA - 26 July 2024. View of leading global biotechnology company Biogen office exterior banner logo sign, Biotech industry
Autoimmune disease
Biogen Seeks To Stand Out in Lupus With New Anti-CD40L Data
Phase III data for dapirolizumab pegol presented at the 2025 conference of the American College of Rheumatology showed quality-of-life benefits in systemic lupus erythematosus that could see Biogen go head-to-head with GSK and AstraZeneca in a blockbuster space.
October 28, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS